Profitelligence Profitelligence · Filing Ledger Open NTRA research →

Form 8-K · Current Report · Filed 2024-12-06

Amended Employment Agreement for Executive Chairman

On December 2, 2024, Natera, Inc. entered into an Amended and Restated Employment Agreement with Matthew Rabinowitz, Ph.D., its Executive Chairman and Co-Founder, effective November 1, 2024. The agreement amends previous terms, detailing continued employment terms, compensation, and severance benefits in case of involuntary termination.

Filer
Natera Inc. NTRA · NASDAQ
Filed
Accession
0001104659-24-126348
CIK
0001604821
Signal
Low impactHealthcare

Items reported

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

Executive Employment Agreement Severance Agreement

Market reaction

Close before filing

$169.02

Next session

-0.7%

Since filing

+58.4%

Latest close

$267.76

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from NTRA reporting the same item, with the next session's move:

About Natera Inc.

Natera Inc., a leading player in the life sciences and diagnostics industry, specializes in developing cell-free DNA testing technologies. This biotechnological firm primarily focuses on non-invasive genetic testing, assisting in maternal-fetal medicine through the screening of high-risk pregnancies with its flagship product, Panorama. In addition to prenatal screening, Natera offers genetic solutions for oncology and organ health, providing critical insights through its comprehensive suite of products. These offerings are especially significant in cancer diagnostics, where Natera's technology helps in early detection, monitoring, and guiding treatment options. The company's innovative approach to DNA analysis enables the identification of genetic conditions and the monitoring of health trends with precision and ease, impacting healthcare providers, patients, and researchers. With its headquarters in San Carlos, California, Natera Inc. is at the forefront of genetic testing advancements, playing a pivotal role in personalizing medicine and revolutionizing patient care by enhancing early diagnosis capabilities and improving clinical outcomes.

Exchange NASDAQ Industry Diagnostics & Research Company website ↗

Never miss another NTRA filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts